ACRP Expands Member Benefits
New for 2009, the Association of Clinical Research Professionals (ACRP), has launched a series of services to expand the online networking and educational resources available to its nearly 20,000 members worldwide.
ACRP Launches “Online Community” as an Expanded Member Benefit
(January 6, 2009, Alexandria, Va.)—New for 2009, the Association of Clinical Research Professionals (ACRP), a nonprofit organization dedicated to strengthening the careers of those engaged in the clinical research enterprise, has launched a series of services that are greatly expanding the online networking and educational resources available to its nearly 20,000 members worldwide.
“Many of the current challenges and new opportunities for the profession in general, and for the association’s members in particular, present themselves in the rapidly evolving online arena, which recent survey results showed is somewhere that our members wanted additional benefits,” says David M. Vulcano, chair of the Association Board of Trustees for ACRP. “Having heard the message loud and clear, ACRP is pleased to institute the Online Community as a way to bring its scattered members closer together so that we can share insights, opinions, and resources with one another, and work in concert toward the betterment of the important functions that clinical research plays in the global community.”
The following exclusive members-only benefits began rolling out on January 5:
• Interactive Member Directory—connecting members with more than 20,000 potential contacts from in excess of 60 countries around the world. The new network will foster collaboration among members by featuring a style that is similar to LinkedIn or Facebook communities, with individualized profiles, blogs, and security settings being among the capabilities that will strengthen the ACRP community bonds.
• Resource Library—housing best practices, SOPs, and articles as a way for members to share up-to-date information with one another. Members will be encouraged to search for, comment on, rank, and contribute to this vast repository of online resources.
• Wiki—featuring an interactive online encyclopedia and glossary, including terms and acronyms, providing members with guidance on the full range of topics related to clinical research.
• eGroups—offering new and improved listserves for the ACRP special interest forums with better readability, customizable subscriptions, and searchable content.
ACRP is based in Alexandria, Va., and devoted to the education of the entire clinical research team of professionals dealing with clinical trials for testing new drugs, medical devices, and therapies on volunteer subjects. For more information about ACRP, visit www.acrpnet.org.
Mission: Provide global leadership to promote integrity and excellence for the clinical research profession.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
